1 week Ago By ABMN Staff
CureVac ( NASDAQ:CVAC – Get Free Report )’s stock price rose 7.5% during mid-day trading on Friday . The company traded as high as $3.
05 and last traded at $3.08. Approximately 220,809 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 809,843 shares.
The stock had previously closed at $2.86. Analyst Ratings Changes Separately, JMP Securities reiterated a “market outperform” rating and set a $16.
00 target price on shares of CureVac in a research report on Friday, February 14th. Read Our Latest Analysis on CVAC CureVac Stock Performance CureVac ( NASDAQ:CVAC – Get Free Report ) last issued its quarterly earnings data on Thursday, April 10th. The company reported ($0.
15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01).
The company had revenue of $15.44 million for the quarter, compared to the consensus estimate of $6.40 million.
CureVac had a return on equity of 21.98% and a net margin of 20.72%.
As a group, sell-side analysts forecast that CureVac will post 0.72 earnings per share for the current year. Institutional Inflows and Outflows Institutional investors and hedge funds have recently bought and sold shares of the company.
Barclays PLC bought a new stake in shares of CureVac in the 3rd quarter worth about $67,000. Public Employees Retirement System of Ohio bought a new stake in CureVac in the third quarter worth about $91,000. Jane Street Group LLC boosted its position in shares of CureVac by 239.
0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after buying an additional 55,867 shares during the period. China Universal Asset Management Co.
Ltd. grew its stake in shares of CureVac by 10.3% during the fourth quarter.
China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock valued at $162,000 after buying an additional 4,425 shares during the last quarter.
Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of CureVac in the third quarter worth approximately $35,000. 17.26% of the stock is owned by hedge funds and other institutional investors.
About CureVac ( Get Free Report ) CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. Featured Stories Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter .
.
